Drugs for IBD, including aminosalicylates, corticosteroids and anti-tumor necrosis factor (TNF) therapies target different aspects of the immune response, but all are hampered by primary and secondary loss of response and have a number of contraindications and adverse effects2–4. The gene discussed is TNF; the disease is inflammatory bowel disease.